← Leaderboards
Eli D Ehrenpreis
University Of Chicago
$141,058
Attributed
$141,058
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$141,058 · 3
By mechanism
R03$75,500 · 1
M01$65,558 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Judy H Cho$53,609,227
- Stephen B. Hanauer$1,604,461
- Eugene B Chang$58,954,761
- Karen Leigh Edelblum$8,422,013
- Clara Abraham$13,251,800
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationCrohn'S DiseaseElectromyographyThalidomideGastrointestinal Disorder ChemotherapyDrug Adverse EffectClinical TrialsWound HealingPeptic UlcerDrug Screening /EvaluationPregnancy TestsGastrointestinal Drug AbsorptionBlood ChemistryBlood TestsDosageAdult Human (21+)MonosaccharidesNutrient Drug InteractionOral AdministrationPharmacokineticsStomach Emptying
Grant awards (5)
OPEN LABEL TRIAL OF THALIDOMIDE IN TREATMENT OF REFRACTORY CROHNS DISEASE$0
M01 · FY2002 · RR
A CLINICAL TRIAL OF THALIDOMIDE FOR CROHN'S DISEASE$75,500
R03 · FY2000 · DK
OPEN LABEL TRIAL OF THALIDOMIDE IN TREATMENT OF REFRACTORY CROHNS DISEASE$32,779
M01 · FY2000 · RR
D XYLOSE ABSORPTION--RELATIONSHIP TO GASTRIC EMPTYING AND PHARMACOKINETICS$32,779
M01 · FY2000 · RR
OPEN LABEL TRIAL OF THALIDOMIDE IN TREATMENT OF REFRACTORY CROHNS DISEASE$0
M01 · FY2000 · RR